HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity:wherein HET, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, integer a and R<sub>3</sub> are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
JORDAN ALLAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-26, Last update posted on www.tib.eu: 2023-10-10, Last updated: 2023-10-13 |
|---|
| Patentnummer: |
EP4104837 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016695410 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016695410 | ||
| 003 | DE-627 | ||
| 005 | 20231013135258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016695410 | ||
| 035 | |a (EPA)EP4104837 | ||
| 035 | |a (EPA)58633036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a JORDAN ALLAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-26, Last update posted on www.tib.eu: 2023-10-10, Last updated: 2023-10-13 | ||
| 520 | |a The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity:wherein HET, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, integer a and R<sub>3</sub> are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a NEWTON REBECCA |4 aut | |
| 700 | 0 | |a WASZKOWYCZ BOHDAN |4 aut | |
| 700 | 0 | |a SUTTON JONATHAN MARK |4 aut | |
| 700 | 0 | |a HYND GEORGE |4 aut | |
| 700 | 0 | |a PAOLETTA SILVIA |4 aut | |
| 700 | 0 | |a FORDYCE EUAN ALEXANDER FRASER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/58633036/publication/EP4104837A1?q=EP4104837 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 26 |c 04 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 04 | ||